Please assess the completion status of the following clinical trial:

Trial Title: Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Type 1or Type 2 diabetes mellitus for at least a year~2. Stable insulin regimen for at least 3 months consisting of multiple daily injections of human regular or rapid acting insulin at meal times and long or intermediate acting insulin as basal. In this protocol multiple daily injections requires at least three injections daily.~3. Total daily insulin dose between 50 and 80 units.~4. If patient is Type 2, can be treated with metformin and/or a thiazolidinedione and/or a sulfonylurea, but other diabetes drugs including α-glucosidase inhibitors, meglitinides, pramlintide exenatide, and DPP-IV's are excluded.~5. HbA1c \> 7.0% and \< 9.0%.~Exclusion Criteria:~1. Recurrent major hypoglycemia or prolonged unstable blood glucose control (as judged by the Investigator).~2. Use of other diabetes drugs including α-glucosidase inhibitors, meglitinides, pramlintide, exenatide or DPP-IV inhibitors (metformin and/or a thiazolidinedione and/or a sulfonylurea are allowed).~3. Intend to use any other concomitant drug therapy (prescription or over-the-counter medications) that can affect blood glucose levels.~4. Have used systemic glucocorticoids within 1 month prior to Screening or currently on glucocorticoids.~5. Have a history of drug or alcohol abuse within 1 year prior to Screening Visit.~6. Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, or neurological disease that would, in the investigator's opinion, preclude safe participation in the study.~7. Have a history of major surgery, e.g. laparotomy, thoracotomy, open orthopedic procedure, etc. within 3 months prior to Screening Visit.~8. Evidence of significant neuropsychiatric disease.~9. Have participated in a medical, surgical, or pharmaceutical investigational new drug/device study in the last 30 days or ≤ 5 half-lives of the investigational drug, whichever is longer, prior to Screening Visit.~10. Blood donation of 500 ml or more in the last 2 months prior to Screening Visit.~11. Evidence of significant active hematological disease.~12. Acute infection with fever.~13. Hemoglobin \< 10 g/dL; AST, ALT ≥ 1.5 times the upper reference limit at Screening.~14. Uncontrolled treated/untreated hypertension (systolic blood pressure \> 155 mmHg and diastolic blood pressure \> 90 mmHg).~15. History of proliferative retinopathy or maculopathy requiring acute treatment~16. Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation.~17. Any condition that the Investigator and/or Sponsor feel would interfere with trial participation or evaluation of results~18. Pregnancy, breast-feeding, intention of becoming pregnant for female patients of child-bearing potential.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy